ReviewPharmacoEconomics2004

Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

Kurt Neeser et al.PubMed ↗Publisher ↗

No numbers read from the abstract.